Cytotoxic effects of mistletoe (Viscum album L.) in head and neck squamous cell carcinoma cell lines

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2316-2322

  Klingbeil, Ma Fátima G ^a   Xavier, Flávia C A ^b   Sardinha, Luiz R ^c   Severino, Patricia ^c   Mathor, Monica B ^d   Rodrigues, Rodrigo V ^a   Pinto Jr , Décio S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^d INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

AKT; Antroposophic medicine; Carcinogenesis; Complementary therapy; CYCLIN D1; Iscador; Mistletoe; Oral squamous cell carcinoma; PTEN; Viscum album

Indexed keywords

CYCLIN D1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; VISCUM ALBUM EXTRACT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESISTANCE; GENE EXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRAIN DIFFERENCE; TONGUE CARCINOMA;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MISTLETOE; PLANT EXTRACTS;

EID: 84885075219     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2732     Document Type: Article

References (40)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
2. Warnakulasuriya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45: 309-316, 2009.
3. Sklenicka S, Gardiner S, Dierks EJ, Potter BE and Bell RB: Survival analysis and risk factors for recurrence in oral squamous cell carcinoma: does surgical salvage affect outcome? J Oral Maxillofac Surg 68: 1270-1275, 2010.
4. Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G and Gorgoulis VG: Advances in the biology of oral cancer. Oral Oncol 43: 523-534, 2007.
5. Miller CS and Johnstone BM: Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91: 622-635, 2001.
6. Scully C and Bagan J: Oral squamous cell carcinoma overview. Oral Oncol 45: 301-308, 2009.
7. Gold KA, Lee HY and Kim ES: Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 115: 922-935, 2009.
8. Corvò R: Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 85: 156-170, 2007.
9. Bernier J: Current state-of-the-art for concurrent chemoradiation. Semin Radiat Oncol 19: 3-10, 2009.
10. Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94: 29-86, 2005.
11. Cicenas J: The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 23: 1-9, 2008.
12. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V and Gutkind JS: Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45: 324-334, 2009.
13. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK and Furnari FB: PCAF modulates PTEN activity. J Biol Chem 281: 26562-26568, 2006.
14. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997.
15. Kurasawa Y, Shiiba M, Nakamura M, Fushimi K, Ishigami T, Bukawa H, et al: PTEN expression and methylation status in oral squamous cell carcinoma. Oncol Rep 19: 1429-1434, 2008.
16. Lundberg AS and Weinberg RA: Control of the cell cycle and apoptosis. Eur J Cancer 35: 531-539, 1999.
17. el-Naggar AK, Steck K and Batsakis JG: Heterogeneity of the proliferative fraction and cyclin D1/CCND1 gene amplification in head and neck squamous cell carcinoma. Cytometry 21: 47-51, 1995.
18. Zuzak TJ, Rist L, Eggenschwiler J, Grotzer MA and Viviani A: Paediatric medulloblastoma cells are susceptible to Viscum album (mistletoe) preparations. Anticancer Res 26: 3485-3492, 2006.
19. Harmsma M, Grommé M, Ummelen M, Dignef W, Tusenius KJ and Ramaekers FC: Differential effects of Viscum album extract Iscador Qu on cell cycle progression and apoptosis in cancer cells. Int J Oncol 25: 1521-1529, 2004.
20. Goedings P: Über die bildung von Viscum album L. Element der Naturwissenschaft 67: 1-23, 1997 (In German).
21. Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, S, et al: Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer 14: 260-267, 2006.
22. Eggenschwiler J, Patrignani A, Wagner U, Rehrauer H, Schlapbach R, Rist L, et al: Gene expression profiles of different breast cancer cells compared with their responsiveness to fermented mistletoe (Viscum album L.) extracts Iscador from oak (Quercus), pine (Pinus), white fir (Abies) and apple tree (Malus) in vitro. Arzneimittelforschung 56: 483-496, 2006.
23. Urech K, Buessing A, Thalmann G, Schaefermeyer H and Heusser P: Antiproliferative effects of mistletoe (Viscum album L.) extract in urinary bladder carcinoma cell lines. Anticancer Res 26: 3049-3055, 2006.
24. Matthes H, Friedel WE, Bock PR and Zänker KS: Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med 10: 430-439, 2010.
25. Maier G and Fiebig HH: Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs 13: 373-379, 2002.
26. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, et al: Frequent genetic and biochemical alterations of the PI3K/Akt/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 114: 242-248, 2005.
27. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK and Testa JR: Amplification of Akt2 in human pancreatic cells and inhibition of Akt2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 93: 3636-3641, 1996.
28. Brazil DP, Yang ZZ and Hemmings BA: Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29: 233-242, 2004.
29. Diehl JA, Zindy F and Sherr CJ: Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11: 957-972, 1997.
30. Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffetz S and Herlyn M: Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinoma. Cancer Res 59: 4876-4881, 1999.
31. Baldin V, Lukas J, Marcote MJ, Pagano M and Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7: 812-821, 1993.
32. Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464, 2005.
33. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
34. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, et al: Role of translocation in the activation and function of protein kinase B. J Biol Chem 272: 31515-31524, 1997.
35. Nicholson KM and Anderson NG: The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 14: 381-395, 2002.
36. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128: 157-170, 2007.
37. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, et al: Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128: 141-156, 2007.
38. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, et al: Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 157: 1097-1103, 2000.
39. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, et al: Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156: 1693-1700, 2000.
40. Cully M, You H, Levine AJ and Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192, 2006.